- About Us
-
A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.
- Vision
-
We aim to become a global pharmaceutical company that promotes health and welfare for all by developing next-generation biopharmaceutical and small molecule pharmaceutical products.
- Core Values
-
- Creativity
-
We solve problems by thinking outside the box.
- Principle
-
We value principles, faith and trust.
- Challenge
-
We meet challenges head-on and continuously look for challenges others are reluctant to take on.
- Global No. 1
-
We emphasize top-tier expertise and competitiveness to lead the global market.
- At a Glance
-
- World’s First
-
Antibody
Biosimilar
- No. of Employees
-
2,145
- Revenue
-
USD 1.53 Billion
- Domestic biologics production&export
-
1st
- Sales Permits in
-
More than 90 countries
- Production Capacity
-
190,000 liters
